Unlock Electronic Signature Legitimacy for Pharmaceutical in European Union with airSlate SignNow

How to eSign a document: electronic signature legitimacy for Pharmaceutical in European Union

hello my name is Martin Harvey I want to introduce you to the EU medicines for all or eum for all Global health initiative [Music] in a nutshell under EU M4 experts from EMA's human medicines committee assess medicines and vaccines that are intended to be used outside of the European Union these medicines are typically used in countries with limited regulatory capacity and often they target diseases that are more common in low and middle income countries a key feature is that eum for all is a collaborative process we work in partnership with the World Health Organization as well as with experts and Regulators from the countries where the medicines are likely to be used and this scheme has facilitated availability and access to some important new medicines I want to share three examples with you in 2016 we gave a positive opinion for the first ever malaria vaccine called moscar X which is specifically intended for children after an extensive pilot the World Health Organization recommended its widespread use in sub-Saharan Africa in 2021. UNICEF estimates that half a million children die each year from Amelia area in Africa alone and this vaccine is expected to help save many young lives each year my second example targets HIV infection ing to who there are some 38 million people living with HIV worldwide many of whom are in Africa and under eum for all the agency gave a positive opinion for the depivarine vaginal ring this was developed by a non-governmental organization specifically to provide an extra option for women to reduce their risk of HIV infection more recently in 2022 we endorsed the Dengue tetravalent vaccine also known as kudenga a vaccine to prevent Dengue Fever now who estimates there are about 390 million Dengue infections each year worldwide and 20 to 25 000 people die each year mostly children medicines assessed through the EU M for all process all go through the same robust assessment as medicines intended for citizens in the European Union and we only give a positive opinion for medicines where the data to demonstrate they can be used safely are effective and of high quality so what are the benefits number one medicines get a seal of approval from an internationally trusted regulatory Authority and this helps promote confidence in the products number two our partnership model Fosters capacity building and exchange of knowledge between Regulators worldwide and number three and most importantly it can speed patient access to Safe effective and quality medicines EMA encourages all developers whether you're a multinational pharmaceutical company or a not-for-profit organization to come and use the eum for all pathway we can support you in this with scientific advice and through our Innovation task force fee waivers and reductions may also be available for small and medium-sized Enterprises for medicines targeting children or for medicines to prevent or treat pandemics please do get in touch with us and thank you for watching foreign